Rare Autoimmune Disease Stays in Remission for Over 15 Years After Immune System Replacement

Two young adults with a rare, aggressive autoimmune disease have remained in remission for more than 15 years after having their immune systems effectively replaced. The cases involve neuromyelitis optica (NMO), a condition in which antibodies attack supporting cells in the brain and spinal cord, often leading to severe disability.

Standard therapies for NMO can reduce relapses, but they are expensive, require lifelong treatment, and do not eliminate the disease-causing antibodies. In this report, researchers from the IRCCS San Raffaele Scientific Institute in Italy describe how allogeneic hematopoietic cell transplantation (alloHCT) produced sustained disease control without the need for ongoing immunosuppressive therapy.

How the transplant treatment works

AlloHCT uses donor stem cells from another individual to rebuild a patient's blood-forming and immune systems. Before the transplant, both 28-year-old patients received the chemotherapy drugs fludarabine and treosulfan to eliminate immune cells, including the B cells responsible for producing the harmful AQP4-IgG antibodies that play a central role in NMO.

After the conditioning treatment, healthy donor stem cells were infused into the bloodstream, where they successfully engrafted and gradually generated a new, functioning immune system. The aim was to achieve an immune "reset" that would restore normal immune regulation and prevent further antibody-mediated attacks on the nervous system.

Long-term outcomes and quality of life

During 15 and 16 years of follow-up, neither patient experienced a relapse or required maintenance immunosuppressive therapy. The disease-causing antibodies disappeared permanently, and laboratory testing demonstrated a stable immune profile consistent with improved immune regulation and tolerance.

The male patient showed measurable neurological improvement and has since fathered two children. According to the researchers, he has resumed a normal life. The female patient did not experience the same degree of neurological recovery but no longer requires medication for NMO and has regained partial use of her arms, achieving what physicians describe as a good quality of life.

The researchers emphasized that no currently approved treatment for NMO allows patients to remain completely treatment-free while maintaining long-term disease control and permanent elimination of pathogenic antibodies. The durability of remission observed in these two cases provides an important benchmark for future therapies.

Risks, complications, and patient selection

Despite these encouraging outcomes, alloHCT remains a high-risk procedure. Following transplantation, the male patient developed chronic immune deficiency requiring regular immunoglobulin infusions and experienced a temporary episode of enlarged lymph nodes. The female patient was later diagnosed with bladder cancer, which was successfully treated surgically.

Neither complication has been definitively linked to the transplant, and the cause of the man's immune deficiency remains unknown. Nevertheless, these cases highlight that replacing the immune system is a major medical intervention that may carry serious, including delayed, complications.

The authors argue that alloHCT should be considered only for carefully selected younger patients with highly aggressive, treatment-resistant NMO or with coexisting autoimmune diseases. They emphasize that each case requires an individualized assessment weighing the risks of transplantation against the potential consequences of ongoing disease activity and lifelong immunosuppressive therapy.

Broader implications for autoimmune disease

AlloHCT has long been used to treat blood cancers and has also shown promise in certain non-malignant disorders, including sickle cell disease. In NMO, however, only a limited number of transplants have been reported, and this study provides the longest follow-up currently available, offering valuable insight into very long-term outcomes.

The findings contribute to the growing body of research investigating immune "reset" strategies for autoimmune diseases, including multiple sclerosis and systemic sclerosis. Some approaches use donor stem cells, as in alloHCT, while others rely on patients' own stem cells to reduce the risk of rejection and graft-versus-host disease.

Researchers and clinicians are now working to optimize conditioning regimens, improve patient selection, and better understand long-term safety. As new biologic therapies and targeted treatments continue to emerge, alloHCT will likely remain a specialized option. However, these cases suggest that, in carefully selected patients, immune system replacement may provide a path toward durable remission and, potentially, a cure.

The study, published in the journal Med, calls for larger collaborative studies to confirm the safety of this approach, identify which patients benefit the most, and compare immune-reset strategies with next-generation antibody-based and cell-based therapies. For now, the two Italian patients remain remarkable long-term examples of what a successful immune system reboot may achieve.